Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $1.8 million.

  • Spero Therapeutics' Non-Current Assets fell 4773.63% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 9015.17%. This contributed to the annual value of $3.3 million for FY2024, which is 9361.69% down from last year.
  • Latest data reveals that Spero Therapeutics reported Non-Current Assets of $1.8 million as of Q3 2025, which was down 4773.63% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Spero Therapeutics' Non-Current Assets peaked at $51.2 million during Q4 2023, and registered a low of $1.8 million during Q3 2025.
  • Over the past 5 years, Spero Therapeutics' median Non-Current Assets value was $11.6 million (recorded in 2022), while the average stood at $13.1 million.
  • As far as peak fluctuations go, Spero Therapeutics' Non-Current Assets skyrocketed by 35568.02% in 2023, and later plummeted by 9361.69% in 2024.
  • Over the past 5 years, Spero Therapeutics' Non-Current Assets (Quarter) stood at $13.2 million in 2021, then decreased by 14.91% to $11.2 million in 2022, then surged by 355.68% to $51.2 million in 2023, then tumbled by 93.62% to $3.3 million in 2024, then tumbled by 43.46% to $1.8 million in 2025.
  • Its Non-Current Assets stands at $1.8 million for Q3 2025, versus $2.7 million for Q2 2025 and $3.0 million for Q1 2025.